solid tumor
Conditions
Interventions
Bevacizumab treatment group :None
Sponsors
Tianjin Cancer Hospital Airport Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Voluntarily agree to participate in the study and sign the informed consent; 2. The patient was confirmed by histopathologically /cytopathological as malignant solid tumor (including non-small cell lung cancer, colorectal cancer, cervical cancer, ovarian cancer, liver cancer, brain glioma); 3. Age =18 years old; 4. The investigators determined that the patient could receive bevacizumab alone or in combination treatment .
Exclusion criteria
Exclusion criteria: 1. Patients who are participating in other blind trials; 2. There is evidence that the patient is a pregnant or lactating woman; 3. The investigator believes that the patient is not suitable to participate in this study for any other conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Other occasional or rare adverse events; | — |
Countries
China
Contacts
Public ContactDong Wang
Tianjin Cancer Hospital Airport Hospital
Outcome results
None listed